
Podcast: Biogen, Bitcoin levels, signals unreliable from US treasuries

Saxo Market Call
Summary: Today we delve into the FDA approval for Biogen's controversial Alzheimer drug and key next steps for the company as this approval is not final. Elsewhere, we look at technical levels for Bitcoin now that it is breaking down again and trading below the lowest daily close since January. A look at the difficulty in getting price signals from the US treasury market, European car-maker valuations, FX stories and more on the call. On today's pod were Peter Garnry on equities, Althea Spinozzi on fixed income and John J. Hardy hosting and on FX.
Listen to today’s podcast and have a look at today’s slide deck.
Follow Saxo Market Call on your favorite podcast app:
If you are not able to find the podcast on your favourite podcast app when searching for Saxo Market Call, please drop us an email at marketcall@saxobank.com and we'll look into it.
Questions and comments, please!
We invite you to send any questions and comments you might have for the podcast team. Whether feedback on the show's content, questions about specific topics, or requests for more focus on a given market area in an upcoming podcast, please get in touch at marketcall@saxobank.com.
Latest Market Insights
Disclaimer